Obesity and long-term outcomes after incident stroke: a prospective population-based cohort study by Akyea, Ralph K. et al.
Obesity and long-term outcomes after incident stroke:
a prospective population-based cohort study
Ralph K. Akyea1* , Wolfram Doehner2,3,4, Barbara Iyen1, Stephen F. Weng1, Nadeem Qureshi1 & George Ntaios5
1Primary Care Stratified Medicine, School of Medicine, University of Nottingham, Nottingham, UK; 2Berlin Institute of Health, Charité—Universitätsmedizin Berlin, BIH Center
for Regenerative Therapies (BCRT), Berlin, Germany; 3Department of Internal Medicine and Cardiology (Virchow Klinikum), Charité Universitätsmedizin Berlin, and German
Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; 4Center for Stroke Research Berlin (CSB), Charité Universitätsmedizin Berlin, Berlin, Germany;
5Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Abstract
Background The association between obesity, major adverse cardiovascular events (MACE), and mortality in patients
with incident stroke is not well established. We assessed the relationship between body mass index (BMI) and MACE in
patients with incident stroke.
Methods The population-based cohort study identified 30 702 individuals from the Clinical Practice Research
Datalink (CPRD GOLD) and Hospital Episode Statistics (HES) databases from the United Kingdom. Individuals were
aged ≥18 years with incident stroke between 1-1-1998 and 31-12-2017, a BMI recorded within 24 months before
incident stroke, and no prior history of MACE. BMI was categorized as underweight (<18.5 kg/m2), normal
(18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obesity class I (30.0–34.9 kg/m2), class II (35.0–39.9 kg/m2)
and class III (≥40 kg/m2). MACE was defined as a composite of incident coronary heart disease, recurrent stroke,
peripheral vascular disease (PVD), heart failure, and cardiovascular-related mortality. Multivariable Cox regression
was used to assess differences in MACE risk between BMI categories.
Results At baseline, 1217 (4.0%) were underweight, 10 783 (35.1%) had a normal BMI, 10 979 (35.8%) had
overweight, 5206 (17.0%) had obesity Class I, 1749 (5.7%) Class II, and 768 (2.5%) Class III. In multivariable analysis,
higher BMI were associated with lower risk of subsequent MACE [overweight: HR 0.96, 95% CI 0.93–0.99)]; PVD
[overweight: 0.65 (0.49–0.85); obesity Class III: 0.19 (0.50–0.77)]; cardiovascular-related death [overweight: 0.80
(0.74–0.86); obesity Class I: 0.79 (0.71–0.88); Class II: 0.80 (0.67–0.96)]; and all-cause mortality [overweight: 0.75
(0.71–0.79); obesity Class I: 0.75 (0.70–0.81); Class II: 0.77 (0.68–0.86)] when compared to those with normal
BMI. The results were similar irrespective of sex, diabetes mellitus, smoking or cancer at time of incident stroke.
Conclusions In patients with incident stroke, overweight or obesity were associated with a more favourable prognosis
for subsequent MACE, PVD, and mortality, irrespective of sex, diabetes mellitus, smoking, or cancer at baseline. As with
other cohort studies, our study demonstrates an association. Randomized control trials should be considered to
robustly evaluate the impact of weight management recommendations on subsequent cardiovascular outcomes in
stroke survivors.
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Introduction
Obesity is an established risk factor for stroke,1 but the
association of increased body mass index (BMI) with survival
after stroke remains contentious. Contrary to evidence in the
general population,2 in patients with established cardiovascu-
lar disease, increased BMI has been shown to be indepen-
dently associated with better outcome.3–6 Many studies
have shown that increased BMI has a protective effect on sur-
vival after stroke,7,8 while other studies have not confirmed
an obesity paradox in patients with stroke.9 The association
between BMI and composite major adverse cardiovascular
event (MACE) and its individual constituent outcomes have,
however, not been studied using a population-based cohort
in patients with any subtype of incident stroke.
Using a large population-based cohort in the United
Kingdom, this study aimed to examine the relationship
between BMI and MACE outcomes during long-term follow-
up in patients with any subtype of incident stroke.
Methods
Data source
This prospective population-based cohort study used the UK
Clinical Practice Research Datalink (CPRD) GOLD database of
anonymized longitudinal primary care electronic health
records,10 linked to secondary care hospitalization data
[Hospital Episode Statistics (HES)],11 national mortality data
[Office for National Statistics (ONS)],12 and social deprivation
data [Index of Multiple Deprivation (IMD) 2015].13 Individuals
included in CPRD GOLD database, from a network of general
practices across the UK, are representative of the UK general
population in terms of sex, age, and ethnicity,10 thereby
validating CPRD GOLD for epidemiological research. This
study was approved by the Independent Scientific Advisory
Committee of the Medicines and Healthcare products
Regulatory Agency (Protocol number 19_023R). Requests to
access CPRD data are made through the Independent
Scientific Advisory Committee (www.cprd.com).
Study population
We identified a cohort of individuals with incident non-fatal
stroke in either primary care (CPRD GOLD) or secondary care
(HES) between 1 January 1998 and 31 December 2017.
Details about this cohort were previously reported.14
Individuals with a record of major adverse cardiovascular
event [including coronary heart disease (CHD), peripheral
vascular disease (PVD), or heart failure] before incident
stroke were excluded. Individuals were followed from date
of incident stroke diagnosis until they developed a major
adverse outcome, died, ceased contributing data, or end of
data collection. The study flow diagram is shown in
Supporting information, Figure S1.
Cohort demographics and baseline characteristics
Age was defined at the time of incident stroke. Ethnicity was
categorized into six groups: Asian, Black, Mixed, Other,White,
and unknown.15 To describe socioeconomic status, the
English Index of Multiple Deprivation 201513 linked to the
individual’s residential postcode was used. IMD is a weighted
mean across the seven domains, hence offers a single score
to describe the concept of deprivation; categorized into
quintiles [Quintile 1 (least deprived group) to Quintile 5
(most deprived group)]. Medication prescriptions (issue of
prescription) at baseline were defined as a prescription
within 12 months before incident stroke. For cholesterol
(low-density lipoprotein, high-density lipoprotein, and total),
BMI, blood pressure measures (diastolic and systolic),
and glomerular filtration rate (GFR), the most recent values/
measures within 24 months before incident stroke were
used. All other comorbidities were defined based on the
latest record before incident stroke.
Body mass index
BMI was categorized according to the WHO criteria as
underweight (BMI < 18.5 kg/m2), normal weight (BMI
18.5–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2), obesity
Class I (BMI 30.0–34.9 kg/m2), obesity Class II (BMI
35.0–39.9 kg/m2), obesity Class III (BMI ≥ 40 kg/m2).16
Accordingly, and in line with accumulating epidemiologic
evidence, we used as reference group (normal weight)
patients with a BMI of 18.5–24.9 kg/m2.17
Outcome measures
First subsequent MACE after incident stroke was the primary
outcome. MACE was defined as a composite of new onset
coronary heart disease, recurrent stroke, PVD, heart failure,
or cardiovascular-related mortality, based on record from
across the linked data sources (CPRD, HES, or ONS registry).
All-cause mortality was considered as a secondary outcome.
The study cohort and outcomes were identified from CPRD
using Read codes, from HES using International Classification
of Diseases, tenth revision (ICD-10) codes and Office of
Population Censuses and Surveys Classification of Surgical
Operations and Procedures (OPCS) revision 4.6 for procedure
codes. All code lists used are available for download online
(www.caliberresearch.org/portal/).18
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Statistical analysis
The Shapiro–Wilk test was used to assess normality of
distribution for continuous variables.19 Kruskal–Wallis test
for continuous data and χ2 test for categorical data were
used to compare baseline characteristics between BMI
categories. The level of missing values ranged between
3.1% for blood pressure measures to 57.4% for GFR. Details
on the proportion of missingness is provided in Table S1. To
estimate missing values for BMI, systolic and diastolic blood
pressures, GFR, high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), and total choles-
terol levels, multiple imputation by chained equations was
used to generate 10 imputed datasets using all the other
available patient variables.20 The imputed datasets were
pooled into a single dataset using Rubin’s rules.21 Differences
in baseline characteristics between those with and without a
BMI record within 24 months of incident stroke is provided in
the Table S2. Event rates between BMI categories were
analysed by multivariable Cox regression models using the
category of normal BMI as reference. Time to event curves
for BMI categories were made for MACE outcomes. Hazard
ratios (HRs) and 95% confidence intervals (95% CI) for the
outcomes according to BMI category were calculated in Cox
regression models adjusted for: (a) age and sex; (b) age,
sex, socioeconomic status, current smoking, history of alcohol
problem, atrial fibrillation, chronic kidney disease, diabetes
mellitus, dyslipidaemia, hypertension, transient ischaemic
attack, prescription of angiotensin-converting enzyme
(ACE) inhibitor, anti-hypertensive, anti-diabetic, anti-platelet,
beta-blocker, calcium channel blocker, non-steroidal
anti-inflammatory drugs, statin potency, diastolic and systolic
blood pressure, GFR, total cholesterol (full adjustment
model). Restricted cubic spline with 3–5 knots (lowest Akaike
information criterion) was used for non-linear relationship
between BMI and outcomes. All statistical analyses were
performed using Stata SE version 16.1 (StataCorp LP). An
alpha level of 0.05 was used for all analysis to define
statistical significance.
Results
A total of 30 702 individuals with baseline BMI record (53%
women) were included in this study. The median age for
the study cohort was 75 years (IQR: 65–82). The distribution
of BMI within the study cohort is present in Figure S2. Most
of the individuals were within the overweight and obesity
categories (60.9%) and 35.1% had normal BMI. Clinical
characteristics and medications prescribed at baseline across
the BMI categories are presented in Table 1 and by sex in
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and had higher prevalence of hypertension and diabetes
mellitus at baseline.
During a median follow-up of 12.9 years (IQR: 7.9–
17.2 years), 20 881 (68.0%) individuals had a subsequent
MACE recorded. The proportion of subsequent MACE
outcomes was similar across the BMI categories. Table 2
details the number and proportion for all the MACE and all
the individual constituent outcomes.
Table 3 Outcomes in body mass index subgroups
Outcomes
<18.5
n = 1217 (4.0%)
HR (95% CI)
25.0–29.9
n = 10 979 (35.8%)
HR (95% CI)
30.0–34.9
n = 5206 (17.0%)
HR (95% CI)
35.0–39.9
i = 1749 (5.7%)
HR (95% CI)
≥ 40 kg/m2
n = 768 (2.5%)
HR (95% CI)
Composite MACE
Age and sex adjusted 1.14 (1.06–1.23) 0.96 (0.93–0.99) 0.98 (0.95–1.03) 1.10 (1.04–1.17) 1.07 (0.97–1.17)
Full adjustment 1.12 (1.05–1.21) 0.96 (0.93–0.99) 0.98 (0.94–1.02) 1.08 (1.01–1.15) 1.04 (0.95–1.14)
CHD
Age and sex adjusted 0.81 (0.53–1.22) 1.00 (0.87–1.15) 1.20 (1.02–1.41) 1.29 (1.01–1.63) 1.01 (0.68–1.51)
Full adjustment 0.85 (0.56–1.29) 0.94 (0.82–1.09) 1.05 (0.89–1.24) 1.06 (0.83–1.35) 0.82 (0.55–1.23)
Recurrent stroke
Age and sex adjusted 1.01 (0.92–1.10) 1.00 (0.97–1.04) 1.00 (0.96–1.05) 1.07 (1.00–1.15) 1.05 (0.94–1.16)
Full adjustment 1.00 (0.91–1.09) 1.01 (0.98–1.05) 1.02 (0.97–1.07) 1.09 (1.02–1.18) 1.06 (0.95–1.18)
PVD
Age and sex adjusted 1.96 (1.17–3.26) 0.71 (0.54–0.93) 1.00 (0.73–1.37) 1.02 (0.62–1.66) 0.28 (0.07–1.14)
Full adjustment 1.91 (1.14–3.19) 0.65 (0.49–0.85) 0.79 (0.57–1.09) 0.70 (0.42–1.17) 0.19 (0.05–0.77)
Heart failure
Age and sex adjusted 1.09 (0.69–1.74) 1.12 (0.93–1.35) 1.60 (1.28–1.99) 2.62 (1.96–3.50) 2.60 (1.63–4.15)
Full adjustment 1.13 (0.71–1.80) 1.05 (0.87–1.26) 1.41 (1.12–1.76) 2.10 (1.56–2.83) 1.97 (1.23–3.17)
Cardiovascular mortality
Age and sex adjusted 1.57 (1.38–1.80) 0.80 (0.74–0.87) 0.82 (0.74–0.91) 0.89 (0.75–1.06) 1.16 (0.90–1.50)
Full adjustment 1.53 (1.34–1.75) 0.80 (0.74–0.86) 0.79 (0.71–0.88) 0.80 (0.67–0.96) 1.02 (0.79–1.32)
All-cause mortality
Age and sex adjusted 1.73 (1.58–1.89) 0.75 (0.71–0.79) 0.76 (0.70–0.81) 0.80 (0.71–0.90) 1.06 (0.89–1.26)
Full adjustment 1.64 (1.50–1.80) 0.75 (0.71–0.79) 0.75 (0.70–0.81) 0.77 (0.68–0.86) 0.99 (0.84–1.18)
CHD, coronary heart disease; HR, hazards ratio; MACE, major adverse cardiovascular event; PVD, peripheral vascular disease.
Full adjustment for age, sex, socioeconomic status, current smoking, history of alcohol problem, atrial fibrillation, chronic kidney disease,
diabetes mellitus, dyslipidaemia, hypertension, transient ischaemic attack, prescription of ACE inhibitor, anti-hypertensive, anti-diabetic,
anti-platelet, beta-blocker, calcium channel blocker, non-steroidal anti-inflammatory drug, statin potency, diastolic and systolic blood
pressure, glomerular filtration rate, total cholesterol.
Reference category: Normal weight patients with a BMI of 18.5–24.9 kg/m2
Table 4 Outcomes in body mass index subgroups excluding patients with cancer at time of incident stroke (n = 25 075)
Outcomes
<18.5
n = 961 (3.8%)
HR (95% CI)
25.0–29.9
n = 9023 (36.0%)
HR (95% CI)
30.0–34.9
n = 4388 (17.5%)
HR (95% CI)
35.0–39.9
n = 1522 (6.1%)
HR (95% CI)
≥40 kg/m2
n = 671 (2.7%)
HR (95% CI)
Composite MACE
Full adjustment 1.13 (1.04–1.22) 0.97 (0.93–1.00) 0.97 (0.93–1.02) 1.07 (1.00–1.15) 1.06 (0.96–1.17)
CHD
Full adjustment 0.99 (0.65–1.52) 0.95 (0.82–1.11) 1.05 (0.87–1.25) 1.06 (0.82–1.37) 0.84 (0.55–1.27)
Recurrent stroke
Full adjustment 1.00 (0.90–1.11) 1.02 (0.98–1.07) 1.02 (0.97–1.08) 1.10 (0.12–1.19) 1.08 (0.97–1.21)
PVD
Full adjustment 1.92 (1.09–3.40) 0.69 (0.51–0.92) 0.73 (0.51–1.05) 0.72 (0.43–1.22) 0.21 (0.05–0.85)
Heart failure
Full adjustment 0.89 (0.49–1.60) 1.05 (0.85–1.30) 1.46 (1.14–1.87) 2.12 (1.53–2.94) 2.11 (1.27–3.50)
Cardiovascular mortality
Full adjustment 1.48 (1.27–1.72) 0.78 (0.71–0.85) 0.77 (0.68–0.86) 0.77 (0.64–0.94) 1.10 (0.84–1.45)
All-cause mortality
Full adjustment 1.68 (1.52–1.86) 0.74 (0.70–0.79) 0.73 (0.67–0.80) 0.75 (0.66–0.86) 1.03 (0.85–1.25)
CHD, coronary heart disease; HR, hazards ratio; MACE, major adverse cardiovascular event; PVD, peripheral vascular disease.
Full adjustment for age, sex, socioeconomic status, current smoking, history of alcohol problem, atrial fibrillation, chronic kidney disease,
diabetes mellitus, dyslipidaemia, hypertension, transient ischaemic attack, prescription of ACE inhibitor, anti-hypertensive, anti-diabetic,
anti-platelet, beta-blocker, calcium channel blocker, non-steroidal anti-inflammatory drug, statin potency, diastolic and systolic blood
pressure, glomerular filtration rate, total cholesterol.
Reference category: Normal weight patients with a BMI of 18.5–24.9 kg/m2
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In multivariable analysis, higher BMI were associated
with lower risk of subsequent MACE [overweight: HR 0.96
(95% CI 0.93–0.99)]; PVD [overweight: HR 0.65 (95% CI
0.49–0.85); obesity Class III: HR 0.19 (95% CI 0.50–0.77)];
cardiovascular-related death [overweight: HR 0.80 (95%
0.74–0.86); obesity Class I: HR 0.79 (95% CI 0.71–0.88);
obesity Class II: HR 0.80 (95% CI 0.67–0.96)]; and all-cause
mortality [overweight: HR 0.75 (95% CI 0.71–0.79); obesity
Class I: HR 0.75 (95% CI 0.70–0.81); obesity Class II: HR 0.77
(95% CI 0.68–0.86)] when compared with those with normal
BMI—Table 3. Tables S4, S5, and S6 present the results
disaggregated by sex, diabetes mellitus, and smoking status
at time of incident stroke, respectively. Tables 4 and S7
presents similar results after excluding 5627 (18.3%) individ-
uals with a cancer diagnosis at baseline and excluding 8735
(28.5%) individuals with first subsequent outcomes within
30 days of incident stroke, respectively. The Kaplan–Meier
curves for MACE and all-cause mortality across the BMI
categories over a 10-year follow-up period is presented in
Figure 1.
Figure 1 (A,B) Kaplan–Meier plots. BMI, body mass index.
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When compared with normal BMI, underweight was
associated with a higher risk of MACE [HR 1.12 (95% CI
1.05–1.21)], PVD [HR 1.91 (95% CI 1.14–3.19)],
cardiovascular-related death [HR 1.53 (95% CI 1.34–1.75)],
and all-cause mortality [HR 1.64 (95% CI 1.50–1.80)].
Individuals who were obese had a higher risk of
subsequent heart failure [obesity Class I: HR 1.41 (95% CI
1.12–1.76); obesity Class II: HR 2.10 (95% CI 1.56–2.83);
obesity class III: HR 1.97 (95% CI 1.23–3.17)] when compared
with those with a normal BMI.
The association between BMI and MACE as well as
all-cause mortality was non-linear as shown by the restricted
cubic splines, Figure 2. The risk for both subsequent MACE
and all-cause mortality outcomes were significantly higher
at lower BMI and lower from BMI greater than 25 kg/m2.
Discussion
In this prospective population-base cohort study of 30 702
patients with incident stroke followed for a median duration
of 12.9 years, overweight or obesity was associated with a
more favourable prognosis for subsequent MACE, PVD,
cardiovascular mortality, and all-cause mortality, irrespective
of sex, diabetes mellitus, smoking, or cancer at time of
incident stroke.
After the first reports of the stroke–obesity paradox,22
several confirmatory reports were subsequently published.23
The stroke–obesity paradox comes in contrast to the
well-established association between obesity and risk of
cardiovascular disease in the general population.24 Different
explanations were proposed to explain this paradoxical
conclusion. It was suggested that this may simply represent
an erroneous finding associated with methodology pitfalls
like reverse causation, that is, low body weight may be an
index for the presence of chronic diseases like cancer, malnu-
trition, infectious disease, smoking duration, and intensity,
which in turn increase mortality.25 For example, in a NHANES
analysis, the obesity paradox was present among persons
with dysglycaemia, but was absent in the subgroup of
never-smokers.26 To identify potential reverse causation in
our analysis, we performed subgroup analyses in patients
with and without diabetes mellitus, current smoking, and
patients without cancer diagnosis at the time of incident
stroke. In our cohort, diabetes mellitus was less prevalent
Figure 2 (A,B) Restricted cubic splines for the association between body mass index (continuous variable) and outcomes. MACE, major adverse car-
diovascular event.
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while current smoking and cancer were more prevalent in
underweight patients. The stroke–obesity paradox was pres-
ent irrespective of diabetes mellitus, smoking, or cancer at
time of incident stroke. Although these findings do not
support the explanation of reverse causation, still it may be
possible that this might have occurred by other chronic
illnesses that we did not consider in our analysis.
Another suggested explanation for the stroke–obesity
paradox was residual confounding.25 In our analysis, the
results were adjusted for many prospectively registered
patient characteristics like age, sex, socioeconomic status,
comorbidities, and concurrent medication. We cannot ex-
clude the possibility that additional unmeasured confounding
bias might have been introduced, for example, comorbidities
that are associated with cardiovascular outcomes, might have
not been equally distributed among BMI strata. However, key
comorbidities of cardiovascular risk are featured within the
metabolic syndrome comprising hypertension, diabetes,
hyperlipidaemia all well associated with excessive body
weight. Those factors were well included in the multivariate
adjusted assessments and—in accordance with common
knowledge—a higher, not lower, prevalence of such comor-
bidities with higher body weight was observed in our study.
Hence a higher risk profile of relevant cardiovascular risk
factors may be concluded for patients with higher BMI.
Main strengths of this analysis can be seen in the large size
of this prospective population-base cohort, the long duration
of follow-up exceeding a decade, and the large number of
outcome events. Moreover, to minimize the risk of bias due
to residual confounding, the results were adjusted for a wide
range of comorbidities and clinical covariates. Also, to
identify potential reverse causal pathways, we performed
subgroup analyses according to sex, diabetes, current
smoking habit, and cancer (excluding those with a diagnosis)
at the time of incident stroke. A limitation of the study was
that BMI was the only marker of obesity that we analysed,
as there were no available data about other anthropometric
markers of obesity like waist-hip-ratio or waist circumference.
Given that BMI is an imperfect marker of obesity, it would
be interesting to see in other cohorts whether the
obesity-paradox remains present when other markers of obe-
sity are analysed. Moreover, combined models showed that
within BMI groups, waist circumference can further stratify
cardiovascular risk.27,28 Finally, our analysis was not designed
to assess the effect of weight management in stroke survivors
as there were no available data on change of weight during
follow-up. Recently, an analysis in the ORIGIN dataset identi-
fied weight loss an independent risk factor for higher mortal-
ity compared to no weight loss.29
From the restricted cubic spline plots, 23 and 25 kg/m2
maybe better BMI cut-off points for increased or decreased
risk of subsequent MACE and all-cause mortality outcomes
respectively for this population-based study. These cut-offs
will need to, however, be explored in other populations. It
is important to note that the conclusions of this analysis as
well as previous reports of the stroke–obesity paradox,
should only be viewed as a putative association and should
not be perceived as proof of causality. Therefore, no recom-
mendations about weight management after stroke should
be based on these conclusions. Ongoing randomized
controlled trials might provide further evidence to guide
weight management recommendations in stroke survivors.
Semaglutide was recently associated with sustained, clinically
relevant reduction in body weight30 and is currently assessed
for the reduction of cardiovascular events in patients
with overweight or obesity and prior cardiovascular disease
including stroke.31
Conclusions
In this prospective population-base cohort study of 30 702
patients with incident stroke followed for a median duration
of 12.9 years, overweight or obesity was associated with a
more favourable prognosis for subsequent MACE, PVD, and
mortality, irrespective of sex, diabetes mellitus, smoking, or
cancer at time of incident stroke.
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